212 related articles for article (PubMed ID: 38761302)
1. Personalized Treatment of Multiple Myeloma in Frail Patients.
Lipof JJ; Abdallah N; Lipe B
Curr Oncol Rep; 2024 May; ():. PubMed ID: 38761302
[TBL] [Abstract][Full Text] [Related]
2. Elderly patients with multiple myeloma: towards a frailty approach?
Zweegman S; Engelhardt M; Larocca A;
Curr Opin Oncol; 2017 Sep; 29(5):315-321. PubMed ID: 28763310
[TBL] [Abstract][Full Text] [Related]
3. Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper.
Grant SJ; Mian HS; Giri S; Boutin M; Dottorini L; Neuendorff NR; Krok-Schoen JL; Nikita N; Rosko AE; Wildes TM; Zweegman S
J Geriatr Oncol; 2021 May; 12(4):499-507. PubMed ID: 33342724
[TBL] [Abstract][Full Text] [Related]
4. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study.
Efficace F; Gaidano G; Petrucci MT; Niscola P; Cottone F; Codeluppi K; Antonioli E; Tafuri A; Larocca A; Potenza L; Fozza C; Pastore D; Rigolin GM; Offidani M; Romano A; Kyriakou C; Cascavilla N; Gozzetti A; Derudas D; Vignetti M; Cavo M
Lancet Healthy Longev; 2022 Sep; 3(9):e628-e635. PubMed ID: 36102777
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Facon T; Cook G; Usmani SZ; Hulin C; Kumar S; Plesner T; Touzeau C; Bahlis NJ; Basu S; Nahi H; Goldschmidt H; Quach H; Mohty M; Venner CP; Weisel K; Raje N; Hebraud B; Belhadj-Merzoug K; Benboubker L; Decaux O; Manier S; Caillot D; Ukropec J; Pei H; Van Rampelbergh R; Uhlar CM; Kobos R; Zweegman S
Leukemia; 2022 Apr; 36(4):1066-1077. PubMed ID: 34974527
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
7. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Facon T; Dimopoulos MA; Meuleman N; Belch A; Mohty M; Chen WM; Kim K; Zamagni E; Rodriguez-Otero P; Renwick W; Rose C; Tempescul A; Boyle E; Manier S; Attal M; Moreau P; Macro M; Leleu X; Lorraine Chretien M; Ludwig H; Guo S; Sturniolo M; Tinel A; Silvia Monzini M; Costa B; Houck V; Hulin C; Yves Mary J
Leukemia; 2020 Jan; 34(1):224-233. PubMed ID: 31427722
[TBL] [Abstract][Full Text] [Related]
8. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review.
Mian H; McCurdy A; Giri S; Grant S; Rochwerg B; Winks E; Rosko AE; Engelhardt M; Pawlyn C; Cook G; Jackson G; Bringhen S; Facon T; Larocca A; Zweegman S; Wildes TM
Blood Cancer J; 2023 Jan; 13(1):6. PubMed ID: 36599867
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Yoon SS; Iosava G; Fujisaki T; Garg M; Iida S; Bladé J; Ukropec J; Pei H; Van Rampelbergh R; Kudva A; Qi M; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):785-798. PubMed ID: 34344638
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty.
Murugappan MN; King-Kallimanis BL; Bhatnagar V; Kanapuru B; Farley JF; Seifert RD; Stenehjem DD; Chen TY; Horodniceanu EG; Kluetz PG
J Geriatr Oncol; 2024 Mar; 15(2):101681. PubMed ID: 38104480
[TBL] [Abstract][Full Text] [Related]
11. New Strategies for the Treatment of Older Myeloma Patients.
Larocca A; Cani L; Bertuglia G; Bruno B; Bringhen S
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345030
[TBL] [Abstract][Full Text] [Related]
12. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Lee HS; Kim K; Lee JJ; Yoon SS; Bang SM; Kim JS; Eom HS; Yoon DH; Lee Y; Shin HJ; Park Y; Jo JC; Lee WS; Do YR; Mun YC; Lee MH; Kim HJ; Kim SH; Kim MK; Lim SN; Park SK; Yi JH; Lee JH; Min CK;
Int J Hematol; 2021 Jan; 113(1):81-91. PubMed ID: 32889695
[TBL] [Abstract][Full Text] [Related]
14. Management of Newly Diagnosed Elderly Multiple Myeloma Patients.
Antoine-Pepeljugoski C; Braunstein MJ
Curr Oncol Rep; 2019 May; 21(7):64. PubMed ID: 31127403
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
16. Treatment Considerations for Transplant-Ineligible Multiple Myeloma.
Elnair R; Holstein S
Oncology (Williston Park); 2021 Apr; 35(4):170-182. PubMed ID: 33886251
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL).
Haider I; Leong DP; Louzada M; McCurdy A; Pond GR; Cameron R; Aljama M; Visram A; Wildes TM; Mian H
Leuk Lymphoma; 2024 Apr; ():1-8. PubMed ID: 38625039
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients.
Bonello F; Boccadoro M; Larocca A
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114320
[TBL] [Abstract][Full Text] [Related]
20. More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected].
DuMontier C; La J; Bihn J; Corrigan J; Yildirim C; Dharne M; Hassan H; Yellapragada S; Abel GA; Gaziano JM; Do NV; Brophy M; Kim DH; Munshi NC; Fillmore NR; Driver JA
Blood Adv; 2023 Oct; 7(20):6275-6284. PubMed ID: 37582048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
